Who
Alan A. Musso
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Fulcrum Therapeutics; Director, Rein Therapeutics; CFO and Treasurer, Bellicum Pharmaceuticals; SVP, Fin+Admin, CFO & Treas, Gyre Therapeutics.
In numbers
- Trades disclosed
- 128
- Buys
- 0
- Sells
- 30
- Bought
- $0
- Sold
- $5.0M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 16 Aug 2006
- Last trade
- 2 Feb 2026
- Last filed
- 4 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Feb 2026filed 4 Feb 2026 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —170,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —170,000 at $0.00 | filing |
| 23 Jul 2025filed 23 Jul 2025 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 24 Jan 2025filed 28 Jan 2025 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —285,000 at $0.00 | filing |
| 2 Dec 2024filed 6 Dec 2024 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 20 Aug 2024filed 22 Aug 2024 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,725 at $0.00 | filing |
| 26 Jan 2024filed 30 Jan 2024 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 17 Jan 2024filed 19 Jan 2024 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —61,822 at $0.00 | filing |
| 31 Oct 2023filed 2 Nov 2023 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,450 at $0.00 | filing |
| 7 Aug 2023filed 9 Aug 2023 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —432,800 at $0.00 | filing |
| 2 Jul 2018filed 5 Jul 2018 | Bellicum Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —52,500 at $0.00 | filing |
| 25 May 2018filed 29 May 2018 | Bellicum Pharmaceuticals | SEC FORM 4 Sold | $49K6,206 at $7.97 | filing |
| 3 Jan 2018filed 5 Jan 2018 | Bellicum Pharmaceuticals | SEC FORM 4 Code M | —1,875 | filing |
| 3 Jan 2018filed 5 Jan 2018 | Bellicum Pharmaceuticals | SEC FORM 4 Code F | $6,912706 at $9.79 | filing |
| 3 Jan 2018filed 5 Jan 2018 | Bellicum Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —1,875 at $0.00 | filing |
| 2 Jan 2018filed 4 Jan 2018 | Bellicum Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 2 Jan 2018filed 4 Jan 2018 | Bellicum Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 11 Dec 2017filed 13 Dec 2017 | Bellicum Pharmaceuticals | SEC FORM 4 Sold | $160K17,117 at $9.33 | filing |
| 27 Nov 2017filed 29 Nov 2017 | Bellicum Pharmaceuticals | SEC FORM 4 Sold | $61K6,206 at $9.89 | filing |
| 3 Jul 2017filed 6 Jul 2017 | Bellicum Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —31,500 at $0.00 | filing |
News
Gyre Therapeutics (NASDAQ:GYRE) vs. GSK (NYSE:GSK) Head-To-Head ContrastGYRE · dailypolitical.com · 19 Oct 2026GSK (NYSE:GSK) versus Gyre Therapeutics (NASDAQ:GYRE) Financial ContrastGYRE · themarketsdaily.com · 15 Oct 2026Contrasting Scienture (NASDAQ:SCNX) & Gyre Therapeutics (NASDAQ:GYRE)GYRE · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Alan A. Musso; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.